These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

862 related items for PubMed ID: 21047224

  • 1. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN.
    N Engl J Med; 2010 Nov 04; 363(19):1801-11. PubMed ID: 21047224
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S.
    Lancet; 2013 Jan 12; 381(9861):125-32. PubMed ID: 23158522
    [Abstract] [Full Text] [Related]

  • 3. Rapamycin and rapalogs for tuberous sclerosis complex.
    Sasongko TH, Ismail NF, Zabidi-Hussin Z.
    Cochrane Database Syst Rev; 2016 Jul 13; 7(7):CD011272. PubMed ID: 27409709
    [Abstract] [Full Text] [Related]

  • 4. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME, López-Laso E, Vicente-Rueda J, Camino-León R, Fernández-Ramos JA, Baena-Gómez MA, Peña-Rosa MJ.
    Rev Neurol; 2014 Dec 01; 59(11):497-502. PubMed ID: 25418144
    [Abstract] [Full Text] [Related]

  • 5. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S.
    Lancet Oncol; 2014 Dec 01; 15(13):1513-1520. PubMed ID: 25456370
    [Abstract] [Full Text] [Related]

  • 6. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
    Trelinska J, Dachowska I, Kotulska K, Baranska D, Fendler W, Jozwiak S, Mlynarski W.
    Pediatr Blood Cancer; 2015 Apr 01; 62(4):616-21. PubMed ID: 25557360
    [Abstract] [Full Text] [Related]

  • 7. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczyński D, Kmieć T, Łojszczyk B, Dunin-Wąsowicz D, Jóźwiak S.
    Eur J Paediatr Neurol; 2013 Sep 01; 17(5):479-85. PubMed ID: 23567018
    [Abstract] [Full Text] [Related]

  • 8. Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex.
    Fukumura S, Watanabe T, Takayama R, Minagawa K, Tsutsumi H.
    J Child Neurol; 2015 Aug 01; 30(9):1192-5. PubMed ID: 25143481
    [Abstract] [Full Text] [Related]

  • 9. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA.
    J Pediatr; 2014 May 01; 164(5):1195-200. PubMed ID: 24518170
    [Abstract] [Full Text] [Related]

  • 10. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.
    Franz DN, Agricola K, Mays M, Tudor C, Care MM, Holland-Bouley K, Berkowitz N, Miao S, Peyrard S, Krueger DA.
    Ann Neurol; 2015 Dec 01; 78(6):929-38. PubMed ID: 26381530
    [Abstract] [Full Text] [Related]

  • 11. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Fogarasi A, De Waele L, Bartalini G, Jozwiak S, Laforgia N, Verhelst H, Petrak B, Pedespan JM, Witt O, Castellana R, Crippa S, Gislimberti G, Gyorsok Z.
    BMC Neurol; 2016 Aug 08; 16():126. PubMed ID: 27502586
    [Abstract] [Full Text] [Related]

  • 12. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA.
    Expert Opin Pharmacother; 2011 Oct 08; 12(14):2265-9. PubMed ID: 21806479
    [Abstract] [Full Text] [Related]

  • 13. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
    Wei CC, Hsiao YP, Gau SY, Wu YT, Wu CT, Wu MH, Tsai JD.
    Dermatology; 2021 Oct 08; 237(3):444-449. PubMed ID: 33032292
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
    Ebrahimi-Fakhari D, Franz DN.
    Expert Opin Pharmacother; 2020 Aug 08; 21(11):1329-1336. PubMed ID: 32338549
    [Abstract] [Full Text] [Related]

  • 15. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
    Jiang T, Du J, Raynald, Wang J, Li C.
    World Neurosurg; 2017 Nov 08; 107():1053.e1-1053.e6. PubMed ID: 28866062
    [Abstract] [Full Text] [Related]

  • 16. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex.
    Cappellano AM, Senerchia AA, Adolfo F, Paiva PM, Pinho R, Covic A, Cavalheiro S, Saba N.
    Childs Nerv Syst; 2013 Dec 08; 29(12):2301-5. PubMed ID: 23743818
    [Abstract] [Full Text] [Related]

  • 17. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
    Cheng S, Hawkins C, Taylor MD, Bartels U.
    Pediatr Neurol; 2015 Sep 08; 53(3):238-242.e1. PubMed ID: 26173783
    [Abstract] [Full Text] [Related]

  • 18. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Major P.
    Aging (Albany NY); 2011 Mar 08; 3(3):189-91. PubMed ID: 21415462
    [Abstract] [Full Text] [Related]

  • 19. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Józwiak S, Stein K, Kotulska K.
    Future Oncol; 2012 Dec 08; 8(12):1515-23. PubMed ID: 23231513
    [Abstract] [Full Text] [Related]

  • 20. Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Franz DN, Agricola KD, Tudor CA, Krueger DA.
    J Child Neurol; 2013 May 08; 28(5):602-7. PubMed ID: 22805244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.